Home Cart Sign in  
Chemical Structure| 185991-07-5 Chemical Structure| 185991-07-5

Structure of AMD 3465 6HBr
CAS No.: 185991-07-5

Chemical Structure| 185991-07-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM).

Synonyms: GENZ-644494 hexahydrobromide; AMD 3465 hexahydrobromide; AMD 3465 (hydrobromide)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AMD 3465 6HBr

CAS No. :185991-07-5
Formula : C24H44Br6N6
M.W : 896.07
SMILES Code : [H]Br.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1
Synonyms :
GENZ-644494 hexahydrobromide; AMD 3465 hexahydrobromide; AMD 3465 (hydrobromide)
MDL No. :MFCD20926342

Safety of AMD 3465 6HBr

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of AMD 3465 6HBr

GPCR

Isoform Comparison

Biological Activity

Target
  • CXCR4

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone-Un cells 100 nM 30 minutes AMD3465 reduced the LASP1-Ago2 interaction Cancers (Basel). 2020 Aug 29;12(9):2455.
Human PBMCs 1.3 nM inhibition of SHIV-89.6P replication Proc Natl Acad Sci U S A. 2008;105(30):10531-10536.
Human PBMCs 2.2 nM inhibition of SHIV-KU1 replication Proc Natl Acad Sci U S A. 2008;105(30):10531-10536.
SuDHL8 500 μM 5 min Evaluate the inhibitory effect of AMD3465 on CXCR4 expression, results showed AMD3465 partially inhibited the binding of [18F]MCFB Mol Pharm. 2019 May 6;16(5):2106-2117.
U2932 500 μM 5 min Evaluate the inhibitory effect of AMD3465 on CXCR4 expression, results showed AMD3465 partially inhibited the binding of [18F]MCFB Mol Pharm. 2019 May 6;16(5):2106-2117.
231S cells 100 nM 30 minutes AMD3465 inhibited the CXCR4-dependent LASP1-Ago2 interaction Cancers (Basel). 2020 Aug 29;12(9):2455.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Pancreatic cancer xenograft model Intraperitoneal injection 10 mg/kg Daily for 28 days To evaluate the effect of AMD3465 in combination with temsirolimus to overcome temsirolimus resistance. Results showed that the combination therapy significantly inhibited tumor growth and reduced cyclin D1 and c-Myc gene expression. Neoplasia. 2012 Aug;14(8):690-701.
CBA/J mice Models of Th1- and Th2-cell-mediated pulmonary granuloma formation Osmotic pump implantation 5 μg/hour (6 mg/kg/day) Continuous delivery for 5 days AMD3465 significantly abrogated type-2 inflammation with reductions in lesion size and eosinophil content as well as abrogated IL-5, IL-10, and IL-13 cytokine production in draining lymph nodes. Am J Pathol. 2006 Aug;169(2):424-32

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.12mL

0.22mL

0.11mL

5.58mL

1.12mL

0.56mL

11.16mL

2.23mL

1.12mL

References

 

Historical Records

Categories